Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BGC515 Capsules in Patients With Advanced Solid Tumors

NCT06452160 is registered in ClinicalTrials.gov with BridGene Biosciences Inc. as lead sponsor.

NCT NCT06452160
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06452160 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BGC515 Capsules in Patients With Advanced Solid Tumors
Lead sponsor
BridGene Biosciences Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
June 27, 2024
Completion date
December 31, 2027
Enrollment
103 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epithelioid hemangioendothelioma(ehe), mesothelioma, solid tumor